Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, N.Y., United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, N.Y.
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Mar 2005

Description:

Patients: This Phase II study involved 16 women with metastatic breast cancer. The median age was 55 years. All but one received chemotherapy before the study, and all had at least one metastatic site.

Treatment: The treatment consisted of imatinib an inhibitor of a number of tyrosine kinase enzymes.

Toxicity: Grade 3-4 toxicities included lymphopenia.

Results: The median overall survival was 6.08 months. The authors concluded that they did not see a significant therapeutic benefit as none of the patients remained on the study after 3 months.

Support: Novartis Pharmaceuticals financially supported this study. Novartis manufactures imanitib.

Correspondence: Clifford A. Hudis, MD





Back